Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials.

Drug Des Devel Ther · 2018 · PMC6038859 · PMID 30013325

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

showed a trendP =0.076so close (0.05 < p ≤ 0.1)

Tenecteplase dosage did not influence safety outcomes ( Figure 5 ), but 0.25 mg/kg dose of tenecteplase subgroup showed a trend for lower risk of any ICH (12.0 vs 22.2% for tenecteplase vs alteplase; RR 0.57; 95% CI: 0.30, 1.06; P =0.076; Figure 5-2B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.